Search Results - Denis Fouque

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Outdated or underrated? The case for low-protein diets in CKD

    Outdated or underrated? The case for low-protein diets in CKD by Denise Mafra, Denis Fouque

    Published 2025-07-01 Get full text
    Article

    Save to List
    Saved in:
  2. 2
    A specifically designed multi-biotic reduces uremic toxin generation and improves kidney function

    A specifically designed multi-biotic reduces uremic toxin generation and improves kidney function by Alice Beau, Jane Natividad, Berengère Benoit, Philippe Delerive, Stéphane Duboux, Yuan Feng, Marie Jammes, Cecile Barnel, Giuseppina Sequino, Claudie Pinteur, Griet Glorieux, Denis Fouque, Hubert Vidal, Laetitia Koppe

    Published 2025-12-01

    Chronic kidney disease (CKD) is characterized by accumulation of uremic toxins (UTs), such as p-cresyl sulfate and indoxyl sulfate, generated through the transformation of tyrosine and tryptophan by the gut microbiota. Using an ex vivo Simulator of the Human Intestinal Microbial Ecosystem (SHIME) co...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  3. 3
    Furosemide and Serum Protein-Bound Uremic Toxin Concentrations in Patients With CKD

    Furosemide and Serum Protein-Bound Uremic Toxin Concentrations in Patients With CKD by Margaux Costes-Albrespic, Natalia Alencar de Pinho, Islam Amine Larabi, Carolla El Chamieh, Solène M. Laville, Denis Fouque, Maurice Laville, Luc Frimat, Jean-Claude Alvarez, Ziad A. Massy, Sophie Liabeuf, Natalia Alencar De Pinho, Dorothée Cannet, Christian Combe, Denis Fouque, Luc Frimat, Aghilès Hamroun, Yves-Edouard Herpe, Christian Jacquelinet, Maurice Laville, Sophie Liabeuf, Ziad A. Massy, Pascal Morel, Christophe Pascal, Roberto Pecoits-Filho, Joost Schanstra, Bénédicte Stengel, Céline Lange, Oriane Lambert, Marie Metzger

    Published 2025-07-01

    Introduction: Furosemide is commonly prescribed to patients with chronic kidney disease (CKD) but may impair the kidney’s excretion of protein-bound uremic toxins (PBUTs) via the organic anion transporters 1 and 3 (OAT1 and OAT3). We evaluated the association between furosemide prescription (status...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  4. 4
    Association of Phenylacetylglutamine and Cognitive Impairment in CKD

    Association of Phenylacetylglutamine and Cognitive Impairment in CKD by Hélène Levassort, Julie Boucquemont, Sophie Liabeuf, Solène M. Laville, Céline Lange, Luc Frimat, Christian Combe, Denis Fouque, Maurice Laville, Christian Jacquelinet, Yves-Edouard Herpe, Islam Amine Larabi, Jean-Claude Alvarez, Natalia Alencar de Pinho, Marion Pépin, Ziad A. Massy, Natalia Alencar de Pinho, Dorothée Cannet, Christian Combe, Denis Fouque, Luc Frimat, Aghilès Hamroun, Yves-Edouard Herpe, Christian Jacquelinet, Maurice Laville, Sophie Liabeuf, Ziad A. Massy, Pascal Morel, Christophe Pascal, Roberto Pecoits-Filho, Joost Schanstra, Bénédicte Stengel, Céline Lange, Oriane Lambert, Marie Metzger

    Published 2025-08-01

    Introduction: Chronic kidney disease (CKD) leads to the accumulation of uremic toxins (UTs). Studies have suggested that UTs are associated with cognitive impairment (CI) in patients with CKD. Recently, studies reported that phenylacetylglutamine (PAG) contributes to the association between CKD and...

    Full description

    Get full text
    Article

    Save to List
    Saved in:

Search Tools: